ACADIA Pharmaceuticals Inc.
ACAD
Classifica tra le azioni
#4655
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Prezzo delle azioni
$18.95
Ultima sincronizzazione: 2026-10-16
Capitalizzazione di mercato
$3.26B
Variazione (1 giorno)
-3.86%
Variazione (1 anno)
-9.29%
Paese
US
Scambia ACADIA Pharmaceuticals Inc. (ACAD)
Categoria
Healthcare
Margine operativo per ACADIA Pharmaceuticals Inc. (ACAD)
Margine operativo al October 2026 TTM: 7.59%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di ACADIA Pharmaceuticals Inc., il margine operativo attuale (TTM) è 7.59%. Alla fine del 2023, il margine operativo era -10.10%.
Storico del margine operativo per ACADIA Pharmaceuticals Inc. da 2000 a 2026
Margine operativo alla fine di ogni anno
| Anno | Margine Operativo | Cambia |
|---|---|---|
| 2026 (TTM) | 7.59% | -68.51% |
| 2024 | 24.10% | -338.61% |
| 2023 | -10.10% | -76.64% |
| 2022 | -43.23% | 22.81% |
| 2021 | -35.20% | -45.74% |
| 2020 | -64.87% | -10.78% |
| 2019 | -72.71% | -34.23% |
| 2018 | -110.56% | -52.77% |
| 2017 | -234.11% | -85.13% |
| 2016 | -1,574.14% | -99.42% |
| 2015 | -269,855.74% | 247.34% |
| 2014 | -77,691.67% | 2,222.82% |
| 2013 | -3,344.72% | 685.81% |
| 2012 | -425.64% | -61.50% |
| 2011 | -1,105.56% | -3,186.43% |
| 2010 | 35.82% | -105.04% |
| 2009 | -710.55% | -83.13% |
| 2008 | -4,212.45% | 407.95% |
| 2007 | -829.31% | 37.50% |
| 2006 | -603.15% | 84.56% |
| 2005 | -326.81% | -42.34% |
| 2004 | -566.76% | 204.35% |
| 2003 | -186.22% | -7.44% |
| 2002 | -201.19% | -51.10% |
| 2001 | -411.39% | 57.42% |
| 2000 | -261.34% | 0.00% |
Margine operativo per aziende simili o concorrenti
| Azienda | Margine Operativo | Differenza del margine operativo | Il paese |
|---|---|---|---|
| 38.59% | -94.92% |
US
|
|
| -149.01% | -119.63% |
US
|
|
| 25.57% | -96.63% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -96.20% |
NL
|
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.